Pharma firm Granules India plunges after USFDA scrutiny
** Shares of Granules India GRAN.NS down 3.5% to 665
rupees
** The pharma firm said U.S. FDA inspection at its Hyderabad
facility concluded with six observations
** Stock fell 4.2% last week, while peer Aurobindo Pharma
ARBN.NS dropped 2.04% and Alembic Pharma ALEM.NS gained 4.4%
(Reporting by Manvi Pant in Bengaluru)
((Manvi.Pant@thomsonreuters.com; +918447554364;))
Recent news on Granules India
See all newsGranules India profit surges as higher sales outweigh cost pressures
Brief: Granules India Q2 Consol Profit 1.82 Billion Rupees
Brief: Granules Says Incorporated Wholly Owned Subsidiary Triton Farmaceutica S.A. De C.V. In Mexico
Brief: Granules Promoter Group Pays 10.93 Billion Rupees For Preferential Issue
Granules India falls after key shareholder trims stake